The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Feasibility study of TAS-118 plus oxaliplatin as perioperative chemotherapy for patients with locally advanced gastric cancer (APOLLO-11).
 
Daisuke Takahari
Honoraria - Bristol-Myers Squibb Japan; Chugai Pharma; Lilly Japan; Ono Pharmaceutical; Taiho Pharmaceutical
Research Funding - Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst)
 
Manabu Ohashi
No Relationships to Disclose
 
Atsuo Takashima
Honoraria - Chugai Pharma; Lilly; Merck Serono; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda
Research Funding - LSK BioPharma; Sumitomo Group; Takeda
 
Takuro Mizukami
Honoraria - Asahi Kasei; Lilly Japan; Merck; Otsuka; Sanofi; Taiho Pharmaceutical; Takeda
Research Funding - Lilly Japan; Ono Pharmaceutical; Taiho Pharmaceutical
 
Naoki Ishizuka
Stock and Other Ownership Interests - Sanofi
Honoraria - Bristol-Myers Squibb Japan; MSD K.K
Research Funding - Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst)
 
Hitoshi Katai
Honoraria - Johnson & Johnson
 
Shinya Mikami
No Relationships to Disclose
 
Takeru Wakatsuki
No Relationships to Disclose
 
Keisho Chin
No Relationships to Disclose
 
Satoshi Ida
No Relationships to Disclose
 
Koshi Kumagai
No Relationships to Disclose
 
Souya Nunobe
No Relationships to Disclose
 
Satoru Iwasa
Honoraria - Chugai Pharma; Daiichi Sankyo; Lilly Japan; Ono Pharmaceutical; Taiho Pharmaceutical
Research Funding - Astellas Pharma (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Lilly Japan (Inst); Merck Serono (Inst); Novartis (Inst); Ono Pharmaceutical (Inst)
 
Miki Ito
No Relationships to Disclose
 
Takeyuki Wada
No Relationships to Disclose
 
Yukinori Yamagata
No Relationships to Disclose
 
Takashi Ogura
No Relationships to Disclose
 
Takeshi Sano
Speakers' Bureau - Johnson & Johnson; Medtronic; Ono Pharmaceutical; Taiho Pharmaceutical
 
Narikazu Boku
Honoraria - Bristol-Myers Squibb Japan; Ono Pharmaceutical; Taiho Pharmaceutical
Research Funding - Ono Pharmaceutical (Inst); Takeda (Inst)
 
Kensei Yamaguchi
Consulting or Advisory Role - Bristol-Myers Squibb Japan; Daiichi Sankyo
Speakers' Bureau - Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo; Lilly; Merck Serono; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda
Research Funding - Boehringer Ingelheim (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Dainippon Sumitomo Pharma (Inst); Eisai (Inst); Gilead Sciences (Inst); Lilly (Inst); MSD Oncology (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Yakult Honsha (Inst)